# Bayer clinical trials: 1,674 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 1,674 trials with Bayer as lead sponsor, 50 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Bayer: 1,674 rows for $83.70, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/bayer

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 1,674
- Recruiting or not yet: 50
- Read on: November 19, 2026

## Trials

The 25 newest of 1,674, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 25, 2026 | NCT07841015 | A Study to Learn More About How Well Finerenone Works in Real-world in People With Type 2 Diabetes and Chronic Kidney Disease in Primary... | Bayer | Observational | Not yet recruiting | Type 2 Diabetes, Chronic Kidney Disease (CKD) Stages G2 to G3b | 800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07841015) |
| September 8, 2026 | NCT07806591 | A Study of Darolutamide Plus Androgen Deprivation Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer in India | Bayer | Observational | Not yet recruiting | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07806591) |
| August 31, 2026 | NCT07795606 | An Observational Study to Learn How Mirena and Other Progestogen Treatments Are Used for Endometrial Protection in Women 40+ With a Uterus... | Bayer | Observational | Active not recruiting | Estrogen Therapy | 456,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07795606) |
| August 27, 2026 | NCT07791160 | Study of Acoramidis in Patients With Transthyretin Amyloid Cardiomyopathy | Bayer | Observational | Recruiting | Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07791160) |
| August 13, 2026 | NCT07762287 | Evaluation of Possible Ways the Body May Process Two Different Forms of Elinzanetant in Healthy Study Participants | Bayer | Phase 1 | Recruiting | Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07762287) |
| August 7, 2026 | NCT07753252 | Phase 1 Study in Healthy Adults to See How Sevabertinib Changes Metformin Levels in the Body | Bayer | Phase 1 | Completed | Healthy Participants | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07753252) |
| July 23, 2026 | NCT07722585 | A Study to Learn About How a New Nurandociguat Tablet is Absorbed and Processed in the Body Compared to an Old Tablet and How Food Affects... | Bayer | Phase 1 | Completed | Chronic Kidney Disease | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07722585) |
| June 26, 2026 | NCT07672119 | A Study to Learn About Heart-Related Risks in Elderly Men With Advanced Prostate Cancer Treated With Enzalutamide or Darolutamide | Bayer | Observational | Recruiting | Prostate Cancer | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07672119) |
| June 17, 2026 | NCT07652723 | A Study to Learn About How Safe BAY3389934 is and How it Affects Blood Clotting When Given Alone or With Aspirin in Healthy Participants | Bayer | Phase 1 | Recruiting | Drug-drug Interaction | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07652723) |
| June 4, 2026 | NCT07625215 | A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation | Bayer | Phase 2 | Recruiting | Atrial Fibrillation | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07625215) |
| May 12, 2026 | NCT07582328 | A Study to Learn More About How Well Oxymetazoline HCl 0.05% Nasal Gel Works and How Safe It Is in Healthy Adults | Bayer | Phase 2 | Completed | Nasal Congestion, Nasal Obstruction | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07582328) |
| May 5, 2026 | NCT07566429 | A Study of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's Disease (J-REGENERATE-PD) | Bayer | Phase 2 | Not yet recruiting | Parkinson Disease | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07566429) |
| April 29, 2026 | NCT07557147 | Single-arm, Multi-center Study Evaluating the Acceptance and Feasibility of a Digital Remote Monitoring Tool Configured for Patients With... | Bayer | Observational | Not yet recruiting | Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07557147) |
| April 28, 2026 | NCT07554469 | An Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease... | Bayer | Observational | Recruiting | Chronic Kidney Disease, Type 2 Diabetes Mellitus | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07554469) |
| April 20, 2026 | NCT07538843 | An Observational Study Conducted in China to Evaluate the Efficacy and Safety of Darolutamide in Combination With Androgen Deprivation... | Bayer | Observational | Recruiting | Non-metastatic Castration-resistant Prostate Cancer | 800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07538843) |
| April 16, 2026 | NCT07535112 | A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has... | Bayer | Phase 1 | Recruiting | Advanced/Metastatic Colorectal Adenocarcinoma | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07535112) |
| April 7, 2026 | NCT07515339 | A Study to Learn More About How Safe Nurandociguat is and How it Affects the Way the Body Processes Rosuvastatin and Dabigatran in Healthy... | Bayer | Phase 1 | Withdrawn | Chronic Kidney Disease | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07515339) |
| March 24, 2026 | NCT07490431 | An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Symptoms | Bayer | Observational | Not yet recruiting | Vasomotor Symptoms (VMS) Associated With Menopause | 2,400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07490431) |
| March 4, 2026 | NCT07450599 | A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men... | Bayer | Phase 2 | Recruiting | High-risk Localized Prostate Cancer | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07450599) |
| March 3, 2026 | NCT07446010 | Post Approval Phase 4 Study to Learn More About How Safe Octocog Alfa is, and How Well it Works in Patients With Severe Hemophilia A in... | Bayer | Observational | Not yet recruiting | Severe Hemophilia A | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07446010) |
| February 24, 2026 | NCT07431294 | A Study to Learn About How Safe Nitroglycerin is and How it Affects the Body When Taken Along With Nurandociguat in People With Coronary... | Bayer | Phase 1 | Not yet recruiting | Stable Coronary Artery Disease | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07431294) |
| February 12, 2026 | NCT07406282 | A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly... | Bayer | Observational | Terminated | Prostatic Neoplasms, Metastatic Hormone-Sensitive Prostate Cancer | 1,399 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07406282) |
| February 9, 2026 | NCT07395804 | How Darolutamide Plus Hormone Therapy Works for Men With Advanced Prostate Cancer in Everyday Medical Practice in Germany | Bayer | Observational | Recruiting | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07395804) |
| February 2, 2026 | NCT07379840 | A Study to Learn More About How Safe Finerenone is and How Well it Works in Adults With Chronic Heart Failure in South Korea | Bayer | Observational | Recruiting | Chronic Heart Failure | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07379840) |
| January 27, 2026 | NCT07368712 | A Methodological Study to Learn More About Kidney Function in Healthy People and in People With Reduced Kidney Function | Bayer | Not applicable | Completed | Acute Kidney Injury, Renal Insufficiency | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07368712) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 347 |
| Phase 1/2 | 20 |
| Phase 2 | 233 |
| Phase 2/3 | 6 |
| Phase 3 | 316 |
| Phase 4 | 110 |
| Not applicable | 125 |
| Observational | 517 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 1,454 |
| Terminated | 100 |
| Recruiting | 41 |
| Active not recruiting | 32 |
| Withdrawn | 28 |
| Not yet recruiting | 9 |
| No longer available | 8 |
| Available | 1 |
| Approved for marketing | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Neoplasms | 80 |
| Atrial Fibrillation | 59 |
| Hemophilia A | 57 |
| Erectile Dysfunction | 51 |
| Renal Insufficiency, Chronic | 49 |
| Prostatic Neoplasms | 43 |
| Multiple Sclerosis | 37 |
| Hypertension, Pulmonary | 37 |
| Diabetes Mellitus, Type 2 | 36 |
| Venous Thromboembolism | 35 |
| Hypertension | 33 |
| Carcinoma, Hepatocellular | 33 |
| Heart Failure | 32 |
| Colorectal Neoplasms | 31 |
| Stroke | 29 |
| Carcinoma, Renal Cell | 29 |
| Endometriosis | 26 |
| Macular Degeneration | 22 |
| Carcinoma, Non-Small-Cell Lung | 22 |
| Venous Thrombosis | 22 |
| Breast Neoplasms | 19 |
| Pulmonary Arterial Hypertension | 19 |
| Hot Flashes | 18 |
| Diabetes Mellitus | 18 |
| Menorrhagia | 18 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Cosmetic products manufacturers in the United States](https://specstream.ai/data/businesses/cosmetic-products-manufacturers/united-states)
- [Manufacturers in the United States](https://specstream.ai/data/businesses/manufacturers/united-states)
- [Tower communication companies in the United States](https://specstream.ai/data/businesses/tower-communication-companies/united-states)
- [Corporate gift suppliers in the United States](https://specstream.ai/data/businesses/corporate-gift-suppliers/united-states)
- [Machinery and tool manufacturers in the United States](https://specstream.ai/data/businesses/machinery-and-tool-manufacturers/united-states)
- [Tobacco companies in the United States](https://specstream.ai/data/businesses/tobacco-companies/united-states)
